Perampanel Patent Expiration
Perampanel is used for controlling seizures in patients with epilepsy. It was first introduced by Catalyst Pharmaceuticals Inc
Perampanel Patents
Given below is the list of patents protecting Perampanel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fycompa | US8772497 | Method for producing 1, 2-dihydropyridine-2-one compound |
Jul 01, 2026
(Expired) | Catalyst Pharms |
| Fycompa | US6949571 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
May 23, 2025
(Expired) | Catalyst Pharms |
Perampanel's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Perampanel:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | National Institute of Mental Health (NIMH) | NA |
RECRUITING
(Sep 8, 2026)
| PHASE1 |
| A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | Eisai Inc. | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | University of California, San Francisco | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | Yale University | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response | Yale University | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |